Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

BloomWell Rx vs Fitstry

BloomWell Rx
Graded #296

Lower grade

vs+0.20000000000000284
Fitstry
Graded #292

Higher grade

The verdict

Fitstry takes it — 61.5/100 to 61.3/100, but only just.

Fitstry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fitstry is the GLP-1 weight-loss program of Weightstry, LLC, a LegitScript-certified, cash-pay telehealth practice focused on women 40+. BloomWell Rx is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBloomWell Rx +24
54
30
Dose & formulationFitstry +11
64
75
Clinical oversightFitstry +10
71
81
Labs & monitoringFitstry +20
53
73
FulfillmentBloomWell Rx +3
70
67
Contract termsBloomWell Rx +8
55
47
BloomWell Rx · left barFitstry · right bar

The numbers

MetricBloomWell RxFitstry
WeighScore61.3/10061.5/100
GradeCC
Scorecard rank#296#292
Semaglutide$199/mo (starting dose, compounded)$179/mo (annual plan, plus a separate fee, compounded)
Tirzepatide$249/mo (starting dose, compounded)$269/mo (annual plan, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
BloomWell Rx

Graded #296 · C

Strengths

  • Transparent pricing — compounded semaglutide from $199/mo, tirzepatide (GLP-1/GIP) from $249/mo
  • Free initial visit; fully online process with flexible dosing options
  • Discloses meds are compounded by a licensed third-party pharmacy; also offers NAD+, sermorelin, glutathione
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)

Where it loses points

  • 'Starts at' pricing — final cost depends on dose and plan
  • Compounding pharmacy partner not named ('licensed third-party pharmacy')
  • Not LegitScript-certified (no certification displayed)
  • Operating medical entity not clearly named (site operated by a marketing agency)
Fitstry

Graded #292 · C

Strengths

  • Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
  • Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
  • Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
  • Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
  • Full compounded lineup — weekly injection, daily oral tablet and microdosing options

Where it loses points

  • Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
  • Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard